Hydra Biosciences, Inc. Presents at 15th Annual Bio CEO & Investor Conference, Feb-12-2013 11:00 AM. Venue: The Waldorf Astoria, 301 Park Avenue, New York, NY 10022, United States.

Zalicus Inc. and Hydra Biosciences, Inc. have entered into a collaboration to advance development of Zalicus' preclinical ion channel modulator product candidates for the treatment of pain. This collaboration brings together the Zalicus portfolio of novel, preclinical ion channel product candidates, representing multiple calcium and sodium channel modulators, with Hydra's expertise in ion channel discovery and preclinical drug development. The goal of the collaboration is to advance ion channel drug candidates into clinical development for the treatment of pain. Under the terms of the agreement, Zalicus will pay Hydra an upfront payment and fund R&D activities at Hydra for a two-year period. During this time, Hydra will perform the preclinical development activities necessary to advance Zalicus' preclinical ion channel product candidates toward clinical development. Zalicus' clinical-stage novel ion channel modulators currently in Phase I clinical development for pain, including Z-160, an N-type calcium channel blocker and Z944, a novel T-type calcium channel blocker, are not included in this collaboration. In addition, Zalicus will retain all intellectual property and commercial rights to its product candidates.

Zalicus Inc. and Hydra Biosciences, Inc. announced that they have entered into a collaboration to advance development of Zalicus' preclinical ion channel modulator product candidates for the treatment of pain. This collaboration brings together the Zalicus portfolio of novel, preclinical ion channel product candidates, representing multiple calcium and sodium channel modulators, with Hydra's expertise in ion channel discovery and preclinical drug development. The goal of the collaboration is to advance ion channel drug candidates into clinical development for the treatment of pain. Under the terms of the agreement, Zalicus will pay Hydra an upfront payment and fund research and development activities at Hydra for a two-year period. During this time, Hydra will perform the preclinical development activities necessary to advance Zalicus' preclinical ion channel product candidates toward clinical development. Zalicus' clinical-stage novel ion channel modulators currently in Phase 1 clinical development for pain, including Z-160, an N-type calcium channel blocker and Z944, a novel T-type calcium channel blocker, are not included in this collaboration. In addition, Zalicus will retain all intellectual property and commercial rights to its product candidates.